XT
TVTX icon

XTX Topco’s Travere Therapeutics TVTX Stock Holding History

XTX Topco’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.63M Buy
63,918
+55,372
+648% +$2.46M 0.05% 591
2026
Q1 		$254K Sell
8,546
-52,134
-86% -$1.56M ﹤0.01% 2623
2025
Q4 		$2.32M Buy
60,680
+50,127
+475% +$1.63M 0.06% 466
2025
Q3 		$252K Buy
+10,553
New +$198K 0.01% 1649
2025
Q2 		– Sell
-52,202
Closed -$935K – 3189
2025
Q1 		$935K Buy
52,202
+23,069
+79% +$468K 0.05% 606
2024
Q4 		$507K Buy
29,133
+14,928
+105% +$264K 0.04% 758
2024
Q3 		$199K Sell
14,205
-40,057
-74% -$417K 0.01% 1447
2024
Q2 		$446K Buy
54,262
+28,480
+110% +$192K 0.04% 713
2024
Q1 		$199K Sell
25,782
-46,607
-64% -$393K 0.03% 1182
2023
Q4 		$651K Buy
72,389
+37,097
+105% +$270K 0.14% 136
2023
Q3 		$316K Buy
35,292
+12,393
+54% +$175K 0.05% 693
2023
Q2 		$352K Buy
+22,899
New +$417K 0.06% 603

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco's TVTX Position: Q2 2026 in Review

XTX Topco increased its Travere Therapeutics (TVTX) stake by 648% in Q2 2026, buying an estimated $2.46M and bringing the position to 63,918 shares worth $3.63M. The position accounts for 0.05% of the portfolio, ranked #591.

XTX Topco first reported a position in TVTX in Q2 2023 and has held it in 12 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • XTX Topco held 63,918 shares of Travere Therapeutics worth $3.63M as of Q2 2026.
  • XTX Topco bought 55,372 Travere Therapeutics shares in Q2 2026, an estimated $2.46M.
  • Travere Therapeutics made up 0.05% of XTX Topco's portfolio in Q2 2026, its #591 holding.
  • XTX Topco first reported a position in Travere Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.